source
- Hims & Hers pivots to branded GLP-1 drugs after striking deal with Eli LillyHims & Hers, which previously emphasized personalized care through compounded products, is changing its business model. The company is now focusing on established brand-name GLP-1 treatments rathe…
- Bayer's Sunharbo becomes first FDA-approved factor XIa inhibitor blood thinnerBayer's oral anticoagulant Sunharbo, known as asundexian, has received FDA approval, making it the first factor XIa inhibitor cleared for use in the United States. The drug is intended to lower th…